NurExone Biologic Inc. announced a pioneering collaboration with the German company, Particle Metrix. In connection with the collaboration, a highly-advanced Nanoparticle Tracking Analysis instrument has been recently placed. At NurExone's laboratory, which is an important milestone in the expansion of NurExone's production and analytic processes.

The newly acquired NTA, which is the first of its kind in Israel, is equipped with capabilities including nanoparticle tracking analysis and advanced colocalization technology. The new system is a ZetaView TWIN Laser System PMX-230 using wavelengths of 520 and 640 nanometers for size, concentration, fluorescence, colocalization and Zeta Potential analysis. As part of the collaboration, the two companies will share analytical data between them in order to improve the colocalization performance of the device at these 2 wavelengths.

NurExone plans to leverage the capabilities of the advanced NTA to validate its methodology for analysis of loaded exosomes, a vital part of the development process of its ExoPTEN drug, targeted at the $2.9 billion global market for patients with acute spinal cord injury. In line with its business strategy of monetizing its knowledge and capabilities, NurExone will also be able to offer the NTA services to other companies developing exosome-based therapies for other indications.